Sort   by:  
 Page size 
Tyrosine kinase inhibitors (TKIs) are used to treat non-small cell lung cancers (NSCLC) driven by epidermal growth factor receptor (EGFR) mutations in the tyrosine kinase domain (TKD). TKI responses vary across tumors driven by the heterogeneous group of exon 19 deletions and mutations, but the mole...
ORGANISM(S): Homo sapiens (Human) 
2023-03-11 | PXD037355 | Pride
Tyrosine kinase inhibtors are used to treat non-small cell lung cancers (NSCLC) driven by epidermal growth factor receptor (EGFR) mutations in the tyrosine kinase domain (TKD). We characterized the dynamics of purified EGFR exon 19 kinase domain mutants by HDX-MS with or withour erlotinib, one of th...
ORGANISM(S): Homo sapiens (Human) 
2023-03-11 | PXD037448 | Pride
Sort   by:  
 Page size